XML 24 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727
Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Available-for-sale securities      
Amortized Cost $ 219,840   $ 285,483
Gross Unrealized Gains 10   35
Gross Unrealized Losses (20)   (122)
Other Than Temporary Impairment Loss     (3,752)
Estimated Fair Value $ 219,830   281,644
Maturity period for marketable securities      
Maximum contractual maturity period 1 year    
Average contractual maturity period 4 months    
Proceeds from sale of available-for-sale securities $ 57,098 $ 5,000  
Cash and cash equivalents      
Available-for-sale securities      
Estimated Fair Value 140,146   95,090
Short-term marketable securities      
Available-for-sale securities      
Estimated Fair Value 79,684   143,698
Marketable securities      
Available-for-sale securities      
Estimated Fair Value 0   42,856
Theravance Biopharma      
Maturity period for marketable securities      
Gain on sale 1,200    
Proceeds from sale of available-for-sale securities 49,400    
U.S. government securities      
Available-for-sale securities      
Amortized Cost 7,499   30,019
Gross Unrealized Gains 4   24
Gross Unrealized Losses 0   0
Other Than Temporary Impairment Loss     0
Estimated Fair Value 7,503   30,043
U.S. government agencies      
Available-for-sale securities      
Amortized Cost 15,965   34,756
Gross Unrealized Gains 2   6
Gross Unrealized Losses 0   (12)
Other Than Temporary Impairment Loss     0
Estimated Fair Value 15,967   34,750
Corporate notes      
Available-for-sale securities      
Amortized Cost 46,241   80,880
Gross Unrealized Gains 4   5
Gross Unrealized Losses (20)   (110)
Other Than Temporary Impairment Loss     0
Estimated Fair Value 46,225   80,775
Commercial paper      
Available-for-sale securities      
Amortized Cost 9,989   34,469
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Other Than Temporary Impairment Loss     0
Estimated Fair Value 9,989   34,469
Ordinary shares of Theravance Biopharma      
Available-for-sale securities      
Amortized Cost     10,269
Gross Unrealized Gains     0
Gross Unrealized Losses     0
Other Than Temporary Impairment Loss     (3,752)
Estimated Fair Value     6,517
Money market funds      
Available-for-sale securities      
Amortized Cost 140,146   95,090
Gross Unrealized Gains 0   0
Gross Unrealized Losses 0   0
Other Than Temporary Impairment Loss     0
Estimated Fair Value $ 140,146   $ 95,090